Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (273)

« Back to Publications

CD4+ tissue-resident memory Th17 cells are a major source of IL-17A in Spondyloarthritis synovial tissue.

Liu F. et al, (2025), Ann Rheum Dis, 84, 1151 - 1163

HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity.

Navid F. et al, (2025), Nat Rev Rheumatol, 21, 77 - 87

Inflammatory disease microbiomes share a functional pathogenicity predicted by C-reactive protein.

Britton GJ. et al, (2025), bioRxiv

Transcriptomic effects of methotrexate on natural killer cells in psoriatic arthritis

Tucker LJ. et al, (2025), RHEUMATOLOGY, 64

Chimeric antigens displaying GPR65 extracellular loops on a soluble scaffold enabled the discovery of antibodies, which recognized native receptor.

Barrett J. et al, (2024), Bioengineered, 15

Pathogenic T-cell clones in axial spondyloarthritis: what is the evidence?

Penkava F. et al, (2024), Rheumatology (Oxford), 63, ii4 - ii6

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial.

Worth C. et al, (2024), Lancet Rheumatol, 6, e537 - e545

Correction to Lancet Rheumatol 2024; 6: e537-45.

(2024), Lancet Rheumatol, 6

Mucosal signatures of pathogenic T cells in HLA-B*27+ anterior uveitis and axial spondyloarthritis.

Paley MA. et al, (2024), JCI Insight, 9

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial

Jones C. et al, (2024), Lancet Rheumatology, 6, E537 - E545

Increased interleukin-26 in the peripheral joints of patients with axial spondyloarthritis and psoriatic arthritis, co-localizing with CD68-positive synoviocytes.

Hammitzsch A. et al, (2024), Front Immunol, 15

Elevated type-17 cytokines are present in axial spondyloarthritis stool.

Brough I. et al, (2024), Discov Immunol, 3

Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis.

Ooms A. et al, (2023), BMJ Open, 13

lterations in the gut microbiome implicate key taxa and metabolic pathways across inflammatory arthritis phenotypes.

Thompson KN. et al, (2023), Sci Transl Med, 15

Comprehensive epigenomic profiling reveals the extent of disease-specific chromatin states and informs target discovery in ankylosing spondylitis.

Brown AC. et al, (2023), Cell Genom, 3

Load More

1
2
3
4
5
6
7
...
»